The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Patient selection for BTK inhibitors
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, The Peter MacCallum Cancer Centre, Melbourne, Australia, describes the characteristics of patients who are suited for Bruton’s tyrosine kinase (BTK) inhibitors. BTK inhibitors have certain advantages over other targeted therapies such as BCL-2 inhibitors as they are easier to administer in elderly patients and result in fewer cases of tumor lysis syndrome. The CLL14 trial (NCT02242942) has additionally suggested BTK inhibitors are more effective in patients with chronic lymphocytic leukemia (CLL) who have certain mutations such as 17p deletions or IGHV mutations. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
